Literature DB >> 4027138

Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

G C Kahn, A R Boobis, M J Brodie, E L Toverud, S Murray, D S Davies.   

Abstract

Phenacetin O-deethylase activity was impaired, both in vivo and in vitro, in poor metabolisers of debrisoquine, consistent with the work of others. No impairment was observed in the oxidation of acetanilide, amylobarbitone or antipyrine in the PM phenotype. There was a good correlation (r = 0.804) between the high affinity component of phenacetin O-deethylase and debrisoquine 4-hydroxylase activities. No such correlation was observed with the low affinity component of phenacetin O-deethylase activity. Although debrisoquine was a competitive inhibitor of phenacetin O-deethylase activity, phenacetin was without effect on debrisoquine 4-hydroxylation. There was also marked differences in the effects of sparteine, guanoxan and alpha-naphthoflavone on the two activities. Cigarette smoking was associated with a significant, two-fold, increase in phenacetin O-deethylase activity whilst debrisoquine 4-hydroxylase activity was not affected. It is concluded that the high affinity component of phenacetin O-deethylase and debrisoquine 4-hydroxylase activities are catalysed by different isozymes of cytochrome P-450 but that these are most probably regulated by closely linked genes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027138      PMCID: PMC1400628          DOI: 10.1111/j.1365-2125.1985.tb02800.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Aryl hydrocarbon (benzo[a]pyrene) hydroxylases in liver from rats of different age, sex and nutritional status. Distinction of two types by 7,8-benzoflavone.

Authors:  F J Wiebel; H V Gelboin
Journal:  Biochem Pharmacol       Date:  1975-08-15       Impact factor: 5.858

3.  Acetophenetidin-induced methemoglobinemia.

Authors:  N T Shahidi
Journal:  Ann N Y Acad Sci       Date:  1968-07-31       Impact factor: 5.691

4.  In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.

Authors:  S V Otton; T Inaba; W A Mahon; W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1982-01       Impact factor: 2.273

5.  Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.

Authors:  D S Davies; G C Kahn; S Murray; M J Brodie; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

6.  Benzo(a)pyrene metabolism and plasma elimination rates of phenacetin, acetanilide and theophylline in man.

Authors:  G Kellermann; M Luyten-Kellermann
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

7.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

Authors:  A R Boobis; M J Brodie; G C Kahn; D R Fletcher; J H Saunders; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.

Authors:  A R Boobis; S Murray; C E Hampden; D S Davies
Journal:  Biochem Pharmacol       Date:  1985-01-01       Impact factor: 5.858

View more
  9 in total

1.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

3.  A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.

Authors:  D Sesardic; A R Boobis; R J Edwards; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Authors:  N A Helsby; S A Ward; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

5.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 6.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

8.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

9.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

Authors:  E K Syvälahti; R Lindberg; J Kallio; M De Vocht
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.